EcoDrugPlus

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSLAFG00000007542
Gene Symbol: PIM2
2 External references
115 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rar Related Orphan Receptor C

Ensembl ID : ENSLAFG00000020960
Gene Symbol: RORC
2 External references
382 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSLAFG00000021967
Gene Symbol: RELA
2 External references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSLAFG00000009804
Gene Symbol: ROS1
2 External references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSLAFG00000011608
Gene Symbol: RAF1
2 External references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSLAFG00000015369
Gene Symbol: ROCK1
2 External references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSLAFG00000007153
Gene Symbol: ROCK2
2 External references
304 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sem1 26s Proteasome Subunit

Ensembl ID : ENSLAFG00000012653
Gene Symbol: SEM1
2 External references
155 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSLAFG00000014637
Gene Symbol: SRC
2 External references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSLAFG00000009659
Gene Symbol: TEK
2 External references
164 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ttk Protein Kinase

Ensembl ID : ENSLAFG00000029449
Gene Symbol: TTK
2 External references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSLAFG00000010355
Gene Symbol: UGCG
2 External references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).